10:07 AM EDT, 08/07/2025 (MT Newswires) -- UroGen Pharma ( URGN ) shares fell 3.5% in early trading on Thursday after the company reported a wider Q2 net loss per share that missed analysts' estimates.

UroGen reported a Q2 net loss Thursday of $1.05 per diluted share, wider than a loss of $0.82 a year earlier.

Analysts polled by FactSet expected a per-share loss of $0.83.

Revenue for the quarter ended June 30 was $24.2 million, up from $21.8 million a year earlier.

Analysts surveyed by FactSet expected $23.1 million.

Price: 19.28, Change: -0.73, Percent Change: -3.65